鹭燕医药
(002788)
| 流通市值：32.55亿 | | | 总市值：33.14亿 |
| 流通股本：3.82亿 | | | 总股本：3.89亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,173,756,306.59 | 20,470,766,084.92 | 15,413,532,406.63 | 10,306,033,349.96 |
| 营业收入 | 5,173,756,306.59 | 20,470,766,084.92 | 15,413,532,406.63 | 10,306,033,349.96 |
| 二、营业总成本 | 5,068,450,829.67 | 20,001,054,777.2 | 15,050,903,211.4 | 10,042,759,659.11 |
| 营业成本 | 4,811,720,633.33 | 18,946,245,237.9 | 14,281,433,662.95 | 9,534,887,241.86 |
| 税金及附加 | 11,144,101.18 | 48,156,149.95 | 34,074,119.91 | 23,290,358.59 |
| 销售费用 | 116,719,960.36 | 467,938,219.31 | 341,694,741.81 | 224,483,488.13 |
| 管理费用 | 78,463,832.55 | 321,236,419.1 | 234,673,637.54 | 154,205,353.75 |
| 研发费用 | 1,365,879.98 | 5,845,992.92 | 3,635,551.77 | 2,737,832.1 |
| 财务费用 | 49,036,422.27 | 211,632,758.02 | 155,391,497.42 | 103,155,384.68 |
| 其中:利息费用 | 47,983,622 | 206,683,877.39 | 152,951,908.08 | 101,711,285.65 |
| 其中:利息收入 | 184,096.79 | 3,837,401.35 | 3,012,156.36 | 2,097,047.95 |
| 加:投资收益 | -5,056,306.36 | -18,730,952.34 | -12,979,289.94 | -9,313,276.97 |
| 资产处置收益 | 1,179.75 | 172,333.63 | 67,986.37 | -25,147.59 |
| 资产减值损失(新) | -120,427.13 | -1,874,339.26 | -289,948.89 | 418,827.59 |
| 信用减值损失(新) | -8,760,515.38 | -813,088.15 | -17,520,254 | -14,859,006.99 |
| 其他收益 | 1,231,027.71 | 9,632,306.15 | 5,285,128.14 | 5,722,376.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 92,600,435.51 | 458,097,567.75 | 337,192,816.91 | 245,217,463.09 |
| 加:营业外收入 | 927,432.07 | 4,524,078.32 | 1,361,343.06 | 1,117,822.66 |
| 减:营业外支出 | 982,792.23 | 9,348,475.99 | 4,749,735.65 | 1,182,106.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 92,545,075.35 | 453,273,170.08 | 333,804,424.32 | 245,153,179.71 |
| 减:所得税费用 | 22,789,976.94 | 105,575,203.58 | 75,903,320.59 | 54,388,975.52 |
| 六、净利润 | 69,755,098.41 | 347,697,966.5 | 257,901,103.73 | 190,764,204.19 |
| 持续经营净利润 | 69,755,098.41 | 347,697,966.5 | 257,901,103.73 | 190,764,204.19 |
| 归属于母公司股东的净利润 | 71,323,645.12 | 345,644,716.96 | 257,346,811.41 | 190,373,536.68 |
| 少数股东损益 | -1,568,546.71 | 2,053,249.54 | 554,292.32 | 390,667.51 |
| (一)基本每股收益 | 0.18 | 0.89 | 0.66 | 0.49 |
| (二)稀释每股收益 | - | - | 0.66 | - |
| 八、其他综合收益 | 23,339.27 | 397,854.6 | -67,892.15 | 1,093,908.95 |
| 归属于母公司股东的其他综合收益 | 23,339.27 | 397,854.6 | -67,892.15 | 1,093,908.95 |
| 九、综合收益总额 | 69,778,437.68 | 348,095,821.1 | 257,833,211.58 | 191,858,113.14 |
| 归属于母公司股东的综合收益总额 | 71,346,984.39 | 346,042,571.56 | 257,278,919.26 | 191,467,445.63 |
| 归属于少数股东的综合收益总额 | -1,568,546.71 | 2,053,249.54 | 554,292.32 | 390,667.51 |
| 公告日期 | 2025-04-22 | 2025-04-22 | 2024-10-22 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |